Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-038 vs Berinert for Acute Hereditary Angioedema Attacks
NCT04898309Phase 3Withdrawn
- Sponsor
- Generium
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Blood Coagulation Factors
- Countries
- 1
01
Overview
A Phase 3 trial of GNR-038 in hereditary angioedema (HAE), sponsored by Generium. Planned start Dec 2021; status: withdrawn.
02
Drugs
GNR-038
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04898309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898309.